Morgan Stanley analyst Craig Hettenbach tells investors that in conversations with ad partners the firm has “heard more negatives than positives on Doximity” and point to tepid growth for pharma digital ad spending. The firm, which adds that “all eyes” will be on FY25 guidance in the next earnings report, keeps an Underweight rating and $25 price target on Doximity shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity short report concerns mostly already known, says Evercore ISI
- Doximity falls after Jehoshaphat questions sales growth in short report
- Jehoshaphat Research announces short position in Doximity
- Unusually active option classes on open March 25th
- Doximity initiated with a Market Perform at Leerink